Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Study of Recombinant Staphylococcus Aureus Vaccine in Healthy Adults
NCT03966040Phase 1Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- May 2019
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial in Staphylococcus aureus infection (4 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoint: Occurrence of solicited adverse reactions after vaccination at 21 days. Started May 2019; status: completed.
02
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT03966040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03966040.